Based on the substantial reduction in total daily insulin dose, near-normoglycemia (as documented by the achieved HbA1c values and CGM metrics) and increased fasting C-peptide levels observed at the end of the observation period, it is plausible that semaglutide treatment may have contributed to prolonging the honeymoon phase of T1D. This evidence concerns the gene INS and type 1 diabetes mellitus.